PULMONARY FIBROSIS FOUNDATION

EIN: 841558631 501(c)(3) Diseases & Disorders

CHICAGO, IL

Total Revenue
$9,251,199
Total Expenses
$7,373,338
Total Assets
$17,464,989
Net Assets
$13,714,117
🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Sign In — Free (10 views/day)

Financial Trends

Organization Details

Formation Year
2000
Legal Domicile
CO
Principal Officer
SCOTT STASZAK
Phone
3122652182
Tax Period
2024-07-01 to 2025-06-30

PULMONARY FIBROSIS FOUNDATION, founded in 2000, is a community nonprofit in the Diseases & Disorders sector that reported $9.3M in total revenue in fiscal year 2024. Revenue grew 12% year-over-year, indicating healthy expansion. The organization ran a surplus of $1.9M, a strong 20% operating margin.

Mission

THE PULMONARY FIBROSIS FOUNDATION IS COMMITTED TO ACCELERATING RESEARCH, EMPOWERING OUR COMMUNITY, AND TRANSFORMING CARE SO THAT EVERYONE WITH PULMONARY FIBROSIS CAN LIVE A BETTER LIFE. OUR ULTIMATE GOAL IS TO FIND A CURE FOR PULMONARY FIBROSIS.

Program Service Accomplishments

Program 1
Expenses: $1,235,403 Revenue: $684,045

PFF REGISTRY: THE PFF REGISTRY PROGRAM RECORDED A TOTAL REVENUE OF $957,196, ENCOMPASSING CONTRIBUTIONS AND SPONSORSHIPS AMOUNTING TO $273,150 AND PROGRAM SERVICE REVENUE TOTALING $684,045. THIS...

Read more

PFF REGISTRY: THE PFF REGISTRY PROGRAM RECORDED A TOTAL REVENUE OF $957,196, ENCOMPASSING CONTRIBUTIONS AND SPONSORSHIPS AMOUNTING TO $273,150 AND PROGRAM SERVICE REVENUE TOTALING $684,045. THIS INITIATIVE SERVES AS A COLLABORATIVE RESEARCH ENDEAVOR, UNITING VARIOUS STAKEHOLDERS SUCH AS PATIENTS, CAREGIVERS, FAMILY MEMBERS, HEALTHCARE PROVIDERS, AND RESEARCHERS WITH THE GOAL OF ADVANCING RESEARCH AND ENHANCING THE QUALITY OF LIFE FOR INDIVIDUALS AFFECTED BY PULMONARY FIBROSIS (PF) AND INTERSTITIAL LUNG DISEASE (ILD).THE GOALS OF THE REGISTRY INCLUDE:1. ESTABLISH A COMPREHENSIVE INFORMATION SOURCE TO ASSIST RESEARCHERS IN ADDRESSING DIAGNOSTIC, TREATMENT, AND POTENTIAL CURE-RELATED QUERIES.2. PROVIDE A DATASET ENABLING RESEARCHERS TO ENHANCE THE QUALITY OF CARE IN US-BASED MEDICAL PRACTICES.3. UTILIZE INFORMATION TO SUPPORT LEGISLATIVE AND ADVOCACY INITIATIVES.4. ENGAGE THE PF AND ILD COMMUNITIES.THE REGISTRY INCLUDES TWO DISTINCT REGISTRIES:1. THE PFF PATIENT REGISTRY GATHERED PHYSICIAN-REPORTED MEDICAL INFORMATION TWICE A YEAR FROM OVER 2000 PATIENTS RECEIVING CARE AT 42 PARTICIPATING PFF CARE CENTERS ACROSS THE UNITED STATES FROM 2016 TO 2022.2. THE PFF COMMUNITY REGISTRY LAUNCHED IN JULY 2022 AND RELIES ON SELF-REPORTED INFORMATION SUBMITTED BY PATIENTS, LUNG TRANSPLANT RECIPIENTS DIAGNOSED WITH PF OR ILD, AS WELL AS THEIR CAREGIVERS AND BIOLOGICAL FAMILY MEMBERS, NEARLY 3,000 INDIVIDUALS HAVE ENROLLED TO DATE.TOGETHER, THESE REGISTRIES COMPILE DATA IN AN ELECTRONIC DATABASE COVERING PATIENT DIAGNOSIS, MEDICAL HISTORY, TREATMENT, QUALITY OF LIFE, AS WELL AS MEDICAL AND FAMILY HISTORY FROM CAREGIVERS AND FAMILY MEMBERS. THE COLLECTED DATA ARE ANONYMIZED AND INDEPENDENTLY MANAGED BY A DATA COORDINATING CENTER. FURTHERMORE, THE PATIENT REGISTRY OBTAINED BLOOD SAMPLES WITH PATIENT CONSENT, WHICH WERE THEN ANONYMIZED AND INDEPENDENTLY MANAGED BY A MEDICAL SPECIMEN STORAGE FACILITY ASSOCIATED WITH THE DATA COORDINATING CENTER.CURRENTLY, OVER 60 RESEARCH PROJECTS HAVE BEEN COMPLETED OR ARE UNDERWAY USING CLINICAL DATA AND SOME UTILIZED BIOSAMPLES AND/OR HRCT SCANS FROM THE PATIENT REGISTRY. MOST OF THESE STUDIES ARE CLINICAL IN NATURE, BUT BASIC/TRANSLATIONAL PROJECTS AND PATIENT-CENTERED RESEARCH ALSO ARE WELL REPRESENTED.

Program 2
Expenses: $822,067 Revenue: $3,650

EDUCATION: TOTAL REVENUE RECOGNIZED FOR EDUCATIONAL PROGRAMS WAS $548,062.THE PULMONARY FIBROSIS FOUNDATION (PFF) IS COMMITTED TO PROVIDING QUALITY DISEASE EDUCATION TO THE PULMONARY FIBROSIS (PF)...

Read more

EDUCATION: TOTAL REVENUE RECOGNIZED FOR EDUCATIONAL PROGRAMS WAS $548,062.THE PULMONARY FIBROSIS FOUNDATION (PFF) IS COMMITTED TO PROVIDING QUALITY DISEASE EDUCATION TO THE PULMONARY FIBROSIS (PF) AND INTERSTITIAL LUNG DISEASE (ILD) COMMUNITY. THE PFF STRIVES TO PROVIDE PATIENTS, CAREGIVERS, FAMILY MEMBERS, AND HEALTHCARE PROVIDERS WITH THE RESOURCES NECESSARY TO MORE FULLY UNDERSTAND PF AND ITS IMPACT AS WELL AS PROVIDE PATIENTS WITH THE TOOLS NECESSARY TO LIVE WITH THE DISEASE AND IMPROVE THEIR QUALITY OF LIFE.THE PFF DISEASE EDUCATION WEBINAR SERIES HAS SERVED AS AN ESSENTIAL PROGRAM TO ADVANCE OUR MISSION OF EDUCATING THE PF AND ILD COMMUNITY. THE WEBINAR SERIES PROVIDES A FREE, CONVENIENT WAY FOR PATIENTS, CAREGIVERS, AND FAMILIES TO LEARN FROM AND CONNECT WITH PF SPECIALISTS ON A VARIETY OF IMPORTANT TOPICS. DURING FY24-25, THE PFF DISEASE EDUCATION WEBINAR SERIES INCLUDED EIGHT WEBINARS. THE PFF DISEASE EDUCATION WEBINAR SERIES TOPICS INCLUDED: LUNG TRANSPLANT, EXPOSURES, DIAGNOSIS, PULMONARY FUNCTION TESTS, NUTRITION, RESEARCH, AUTOIMMUNE DISEASES, AND MORE. THE PFF DISEASE EDUCATION WEBINAR SERIES HOSTED OVER 1,500 LIVE ATTENDEES. WEBINARS ARE RECORDED AND AVAILABLE FOR VIEWING ON BOTH THE PULMONARY FIBROSIS FOUNDATION WEBSITE AND YOUTUBE CHANNEL. WEBINARS FROM THE PFF DISEASE EDUCATION WEBINAR SERIES FROM THIS TIMEFRAME HAVE AMASSED OVER 10,000 VIEWS ON YOUTUBE ALONE. IN ADDITION TO THE PFF DISEASE EDUCATION WEBINAR SERIES, THE FOUNDATION HAS DEVELOPED A LIBRARY OF DISEASE EDUCATION MATERIALS FOR PULMONARY FIBROSIS PATIENTS, CAREGIVERS, FAMILY MEMBERS, AND FRIENDS. DURING FY24-25, THE PULMONARY FIBROSIS FOUNDATION DEVELOPED THE FOLLOWING MATERIALS: TRANSLATION OF "COMMON HEALTH RESEARCH TERMS: A GUIDE FOR PEOPLE LIVING WITH PULMONARY FIBROSIS" IN SPANISH, "LUNG BIOPSY FOR INTERSTITIAL LUNG DISEASE" FACT SHEET, "GRAPHIC ILLUSTRATION OF LIQUID OXYGEN", AND "RECURSOS DE FIBROSIS PULMONAR" RESOURCE PAGE OF ALL EDUCATIONAL MATERIALS TRANSLATED INTO SPANISH.

Program 3
Expenses: $544,405 Revenue: $848,845

CORPORATE PARTNERSHIPS:TOTAL REVENUE RECOGNIZED FOR CORPORATE PARTNERSHIPS WAS $1,136,558, WHICH INCLUDED CONTRIBUTIONS AND SPONSORSHIPS OF $285,000, IN ADDITION TO THE PROGRAM SERVICE REVENUE OF...

Read more

CORPORATE PARTNERSHIPS:TOTAL REVENUE RECOGNIZED FOR CORPORATE PARTNERSHIPS WAS $1,136,558, WHICH INCLUDED CONTRIBUTIONS AND SPONSORSHIPS OF $285,000, IN ADDITION TO THE PROGRAM SERVICE REVENUE OF $848,845.THE PFF SEEKS SPONSORSHIPS TO SUPPORT ITS MISSION-DRIVEN ACTIVITIES FROM PATIENT-SERVICE AND EDUCATION TO RESEARCH INITIATIVES. DURING THIS FISCAL YEAR, THE PFF CORPORATE PARTNERSHIPS TEAM CONTINUED TO SECURE SPONSORSHIP FOR THE PFF SUMMIT, THE WORLD'S LARGEST CONFERENCE DEDICATED TO PULMONARY FIBROSIS (PF) AND INTERSTITIAL LUNG DISEASE (ILD) RESEARCH AND EDUCATION. THE TEAM ALSO BEGAN SECURING SUPPORT FOR SEPTEMBER'S PULMONARY FIBROSIS AWARENESS MONTH, THE PFF EDUCATION SYMPOSIUM-OUR VIRTUAL CONFERENCE FOR PATIENTS AND CAREGIVERS-ALONG WITH KEY PROGRAMS INCLUDING THE PFF CARE CENTER NETWORK, THE PFF SCHOLARS PROGRAM, THE PFF REGISTRY, THE PATIENT EDUCATION MATERIALS PROGRAM, THE PFF SUPPORT GROUP LEADERS NETWORK, THE PFF AMBASSADORS PROGRAM, AND THE PFF DISEASE EDUCATION WEBINAR SERIES.THE PFF FURTHER ADVANCED ITS WORK WITH THE PFF CORPORATE COMMITTEE, WHICH SERVES AS A COLLABORATIVE FORUM FOR INDUSTRY PARTNERS TO ENGAGE WITH THE FOUNDATION'S LEADERSHIP AND VOLUNTEER NETWORK AND TO SUPPORT SHARED LEARNING ACROSS THE PF COMMUNITY. THIS YEAR, THE PFF ALSO LAUNCHED THE CLINICAL TRIAL INNOVATION WEBINAR SERIES, CREATING ADDITIONAL OPPORTUNITIES FOR TRIAL SPONSORS TO HIGHLIGHT THEIR RESEARCH AND OFFERING THE PF AND ILD COMMUNITY ANOTHER AVENUE TO STAY INFORMED ABOUT EMERGING SCIENTIFIC AND CLINICAL DEVELOPMENTS.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Sign In — Free (10 views/day)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $7,996,521
Program Service Revenue $1,581,702
Investment Income $632,494
Other Revenue $-959,518
TOTAL REVENUE $9,251,199

Expense Breakdown

Grants Paid $620,294
Salaries & Benefits $4,134,984
Fundraising Expenses $1,146,352
Program Expenses $4,950,416
Other Expenses $2,618,060
TOTAL EXPENSES $7,373,338

Year-over-Year Comparison

2024 2023 Change
Revenue $9,251,199 $8,276,217 +0.1%
Expenses $7,373,338 $9,009,001 -0.2%
Net Income $1,877,861 $-732,784 -3.6%
Key Indicators
Grants to Organizations Grants to Individuals Lobbying Political Activity Foreign Activities Donor Advised Fund Schedule B Required
🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Sign In

Governance

Voting Members
15
Independent Members
15
Employees
39
Volunteers
4833

Governance Policies

Conflict of Interest Policy
Whistleblower Policy
Document Retention Policy

Special Practices & Reported Activities

Operated a School
Operated a Hospital
Provided First Class Travel
Reported Conflict of Interest
Reported Asset Diversion
Excess Benefit Transaction
Made Political Expenditures
Engaged in Lobbying
Operated Donor Advised Fund
Maintained Art Collections
Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers
6
$639,741
Total Directors
16
$0
Key Employees
1
$216,084
Highest Compensated
5
reported
Name Title Hours/Week Role Reportable Comp Other Comp Total
SCOTT STASZAK PRESIDENT & CEO 40.00
Officer
$421,578 $11,090 $432,668
FRANCK RAHAGHI FORMER PRESIDENT & CEO 40.00
$284,230 $5,808 $290,038
SETH KLEIN CHIEF DEVELOPMENT OFFICER 40.00
Key Emp
$209,028 $7,056 $216,084
JESSICA SHORE SR. VP, CLINICAL AFFAIRS AND QUALITY 40.00
Highest
$202,398 $7,013 $209,411
JANET BIANCHETTA CHIEF FINANCIAL OFFICER 40.00
Officer
$184,343 $22,730 $207,073
KATHERINE BEIN VP, ADVOCACY AND PROGRAMS 40.00
Highest
$158,916 $31,572 $190,488
JENNIFER MEFFORD VP, CORPORATE PARTNERSHIPS 40.00
Highest
$172,561 $6,088 $178,649
ZOE BUBANY VP, BOARD AND EXTERNAL RELATIONS 40.00
Highest
$141,984 $21,979 $163,963
AMY WARDZALA VP, DEVELOPMENT 40.00
Highest
$132,201 $27,443 $159,644
WAYNE PAN MD PHD MBA CHAIR 1.00
Officer Director
$0 $0 $0
PATRICIA ROSA VICE CHAIR 1.00
Officer Director
$0 $0 $0
MARTIN ATTWELL SECRETARY 1.00
Officer Director
$0 $0 $0
LAURIE CHANDLER CFP TREASURER 1.00
Officer Director
$0 $0 $0
GRANT BALLANTYNE DIRECTOR 1.00
Director
$0 $0 $0
HAROLD R COLLARD MD DIRECTOR 1.00
Director
$0 $0 $0
TERENCE HALES DIRECTOR 1.00
Director
$0 $0 $0
JULIE HALSTON DIRECTOR 1.00
Director
$0 $0 $0
JEFF HARRIS DIRECTOR 1.00
Director
$0 $0 $0
SUSAN JACOBS RN MS DIRECTOR 1.00
Director
$0 $0 $0
HEATHER KAGEL DIRECTOR 1.00
Director
$0 $0 $0
PJ KAMANI DIRECTOR 1.00
Director
$0 $0 $0
DEVI KUMAR-NAMBIAR JD MBA DIRECTOR 1.00
Director
$0 $0 $0
DAVID MCNINCH DIRECTOR 1.00
Director
$0 $0 $0
WILLIAM SCHMIDT DIRECTOR 1.00
Director
$0 $0 $0
KENNETH FANG MD DIRECTOR - TERM 1.00
Director
$0 $0 $0
Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year Revenue Expenses Assets Net Income
2025 $9,251,199 $7,373,338 $17,464,989 $1,877,861
2024 $8,276,217 $9,009,001 $15,320,155 $-732,784
2023 $11,816,537 $10,341,815 $16,794,445 $1,474,722
2022 $11,007,903 $9,685,619 $17,064,469 $1,322,284
2021 $8,965,595 $8,341,845 $14,745,592 $623,750
2020 $10,702,044 $11,291,623 $10,892,804 $-589,579
2019 $10,448,685 $8,488,184 $10,914,467 $1,960,501
2018 $8,743,466 $8,344,215 $8,884,514 $399,251
Explore More Nonprofits
Top 100 Nonprofits in Illinois Largest U.S. Nonprofits Best Rated Nonprofits Most Efficient Nonprofits

Compare PULMONARY FIBROSIS FOUNDATION with other nonprofits in Illinois and across the country.